earnings
confidence high
sentiment positive
materiality 0.85
Arcutis reports Q2 net loss $67.4M; FDA approved ZORYVE for plaque psoriasis
Arcutis Biotherapeutics, Inc.
2022-Q2 EPS reported
-$2.58
- FDA approved ZORYVE (roflumilast cream) for plaque psoriasis in patients 12+; launch expected in coming weeks.
- Positive Phase 3 topline for roflumilast foam in seborrheic dermatitis; NDA submission planned Q1 2023.
- Completed enrollment in INTEGUMENT-1 atopic dermatitis trial; topline data by end of 2022.
- Cash $283.4M at June 30; pro forma ~$570M after $162M equity net + $125M debt draw.
- Q2 net loss $67.4M ($1.31/sh) vs $42.0M ($0.84/sh) in Q2 2021, driven by R&D and G&A increases.